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Abstract: In the liver, adiponectin regulates both glucose and lipid metabolism and exerts an
insulin-sensitizing effect. The binding of adiponectin with its specific receptors induces the activation
of a proper signaling cascade that becomes altered in liver pathologies. This review describes the
different signaling pathways in healthy and diseased hepatocytes, also highlighting the beneficial
role of adiponectin in autophagy activation and hepatic regeneration.
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1. Adiponectin in Healthy Liver
1.1. Introduction
Adiponectin is one of the several hormones secreted by adipose tissue [1]. Besides the latter,
several other tissues are autocrine for adiponectin production, such as bone [2,3], placenta [4],
cardiomyocytes [5], pituitary gland [6], and skeletal muscle [7], thus generating a local high
concentration of the hormone. Adiponectin is secreted as a monomer called “full-length” adiponectin
(fAd) which associates to form complexes with different molecular weights circulating in the plasma [8].
In the local microenvironment, fAd can be cleaved in the “globular form” adiponectin (gAd) by the
elastase secreted by activated monocytes, neutrophils [9], and macrophages [10], thus suggesting that
the conversion of fAd into gAd could be driven by local inflammation. In plasma, adiponectin circulates
as three complexes called low molecular form (LMW, composed of fAd trimer), middle molecular form
(MMW, composed of fAd hexamer), and high molecular form (HMW, composed of the association
of 12–18 fAd). Distinct downstream biological effects depend on the complex distribution in the
plasma [11]. For example, males have lower levels of HMW with respect to females, accounting for
the different total levels of adiponectin. HMW complex induces a more marked decreased of glucose
following intraperitoneal HMW injection in mice [11]. Correct adiponectin folding and assembly is
key step in the regulation of plasma levels and complex distribution. The assembly and secretion
of HMW requires the hydroxylation and glycosylation of four lysines on adiponectin. Mutations on
these sites greatly decreased HMW concentration in plasma, thus leading to decreased biological
effects [12]. Moreover, hexamers of adiponectin require the formation of the inter-trimeric disulfide
bond at cysteine 39 (cysteine 36 in human adiponectin). Mutation of this cysteine firstly abolishes
hexamer formation and then HMW complexes [13]. Adiponectin binds at two specific receptors,
AdipoR1 and AdipoR2, which belong to the seven-transmembrane domain receptor family but are not
coupled to G protein. The two receptors are differently expressed among tissues, since AdipoR1 is
ubiquitously produced, while AdipoR2 is predominantly expressed in the liver [14].
Hepatic stellate cells (HSC) and Kupffer cells constitutively express the same amount of AdipoR1
and AdipoR2 [15,16]. HSC are activated following a trauma and lead to the secretion of collagen and
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to the formation of scar tissue, leading to chronic fibrosis or cirrhosis. Kupffer cells are key mediators
of both liver injury and repair.
Binding experiments showed that fAd and gAd have different affinities for AdipoR1 and AdipoR2.
Indeed, fAd has higher affinity for AdipoR2, while gAd preferably interacts with AdipoR1 [17].
In addition to AdipoR1 and AdipoR2, T-cadherin, a glycosylphosphatidylinositol-anchored protein,
is the receptor for the hexameric and high molecular weight complexes of adiponectin [18]. To date,
many studies have shown that T-cadherin exerts its effects in healthy and diseased vascular
endothelium [19,20].
1.2. Signaling Pathway of Adiponectin in Healthy Liver
In healthy liver, adiponectin controls the metabolism of both glucose and lipids, decreasing
gluconeogenesis and stimulating glycolysis and fatty acid oxidation. These metabolic effects
occur through the binding of gAd to AdipoR1 and fAd to the specific hepatic receptor AdipoR2.
Following the binding of the ligand to the receptor, the adaptor protein phosphotyrosine interaction,
pH domain, and leucine zipper containing 1 (APPL1) associate to AdipoR1 or AdipoR2. This binding
involves the phosphotyrosine domain of APPL1 and the N-terminal domain of the receptor [21] and
requires the formation of the homodimer APPL1:APPL1 [22]. The two receptors trigger two distinct
signaling pathways, since AdipoR1 promotes AMP-activated kinase (AMPK) activation while AdipoR2
stimulates peroxisome proliferator-activated receptor α (PPARα) cascade. AMPK is partially activated
by the binding to AMP and becomes totally activated following phosphorylation on threonine 172
by the serine/threonine protein liver kinase B1 (LKB1). Activated AMPK promotes the inhibition
of phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) transcription,
thus leading to the decrease of gluconeogenesis [23]. In addition, AMPK blocks lipid synthesis via
the inhibitory phosphorylation of Acetyl-CoA carboxylase (ACC) that catalyzes the synthesis of
malonyl-CoA. Malonyl-CoA is both the precursor of fatty acid biosynthesis and a potent inhibitor of
carnitine palmitoyl transferase I (CPT-I), the enzyme that controls the transfer into the mitochondria
of the long-chain fatty Acyl-CoA for fatty acid oxidation. Therefore, adiponectin-AMPK signaling
promotes lipid catabolism and opposes triglyceride formation in the liver [24]. Activated AMPK
phosphorylates Ser372 of the sterol regulatory element binding protein 1c (SREBP-1c), leading to the
repression of SREBP-1c, a master regulator of fatty acid synthesis [25,26]. In the liver, free fatty acid
burning is due also to the signaling cascade triggered by PPARα, which cooperates with AMPK in
promoting fatty acid combustion [14].
Although it was shown that AdipoR1 and AdipoR2 regulate glucose and fatty acid metabolism
via the activation of AMPK and PPARα pathways, additional signaling molecules participate at the
pleiotropic actions of adiponectin in the liver. A recent paper describing the crystal structure of
AdipoR2 bound to a free fatty acid molecule revealed an intrinsic basal ceramidase activity of the
receptor that is enhanced by adiponectin binding [27]. The involvement of adiponectin in the decrease
of intracellular level of ceramide has previously been reported. Adiponectin, through its receptors
AdipoR1 and AdipoR2, induces ceramidase activation and thus leads to decreased levels of hepatic
ceramide and promotes ceramide catabolism with the formation of sphingosine-1 phosphate in an
AMPK-independent mechanism [28]. This peculiar function of adiponectin has been further confirmed
in mice overexpressing AdipoR1 and AdipoR2 in the liver. Increased levels of adiponectin receptors
lead to reduced ceramide levels and the amelioration of total body glucose and lipid homeostasis in an
adiponectin-dependent mechanism [29]. High intracellular levels of ceramide greatly compromise
insulin signaling, thus predisposing the liver to the onset of insulin resistance and the development
of type II diabetes [30]. In agreement, obese individuals with lowered glucose tolerance and insulin
sensitivity show enhanced ceramide levels and high ceramide synthase expression in visceral white
adipose tissue [31]. In mice, the deletion of ceramide synthase leads to decreased ceramide and
improved glucose tolerance and insulin sensitivity under high-fat diet challenge [31]. The beneficial
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effects of adiponectin, specifically its insulin-sensitizing effect, are probably closely associated to the
ceramidase activity of its own receptors.
Animal-based studies have demonstrated that adiponectin possesses potent protective activities
against various forms of liver injuries [32]. Although the mechanism is not yet clear, some evidences
suggest that adiponectin directly opposes the damaging effects of TNFα within the liver tissue [33].
In animal models of both alcoholic and non-alcoholic steatohepatitis, exogenous adiponectin reduces
hepatomegaly, depletes lipid accumulation, quenches hepatic inflammation, and decreases hepatic
expression and plasma concentrations of TNFα. In fact, inflammatory cytokines are key mediators
of hepatic inflammation, cell death, and fibrosis, as well as regeneration after massive or small
liver injury [32]. In particular, TNFα alters lipid metabolism by interfering with several crucial
transcriptional regulators, such as SREBP-1c [34]. It has been further demonstrated that TNFα provokes
the processing of SREBP-1c in ethanol-exposed hepatoma cell lines, resulting in the inappropriate
induction of lipogenic enzymes, thus suggesting that adiponectin may counteract hepatic lipid
accumulation through the antagonism of TNFα [35]. Adiponectin levels are negatively associated
with mediators of inflammation, including interleukin-6 (IL-6) and C-reactive protein (CRP), and
positively related to the anti-inflammatory cytokine IL-10 [36]. In the liver, cytokines such as IL-6 and
TNFα are mainly produced from Kupffer cells and HSC, and partly from inflamed hepatocytes [32,37].
In agreement with the anti-inflammatory role of adiponectin, recent studies have demonstrated that
hypoadiponectinemia is associated with inflammasome activation. Inflammasome is a multiprotein
complex that plays a crucial role in the proteolytic activation by caspases of the cytokines belonging to
the interleukin family [38]. It has been reported that hypoadiponectinemia promotes the activation
of the inflammasome that is responsible for vascular endothelium dysfunction. This event occurs
through a mechanism involving the formation of oxidative and nitrative stress [39]. Moreover, gAd
inhibits interleukin-1β (IL-1β) production following lipopolysaccharide stimulation in macrophages.
In these cells, gAd suppresses the activation of inflammasome through autophagy induction and
AMPK signaling activation [40]. The main signaling cascades triggered by adiponectin in the liver are
shown in Figure 1.
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receptor α; SCREB-P1c, sterol regulatory element binding protein 1c; TNFα, tumor necrosis factor α. 
Figure 1. Main signaling pathways of adiponectin in healthy liver. AdipoR1 activates AMPK pathway,
whereas AdipoR2 activates peroxisome proliferator-activated receptor α (PPARα). Connections
between AdipoR1/AdipoR2 signaling, TNFα, ceramide, and oxidative stress are described in the
text. The final biological effects of each signaling pathway are shown following the yellow arrows.
Abbreviations: ACC, Acetyl-CoA carb xylase; ACO, Acyl CoA oxidase; AdipoR1, Adiponectin
receptor 1; AdipoR2, Adiponecti recept r 2; AMPK, AM -activated r tein kinase; APPL1, adaptor
protein phosphotyrosine interaction, pH domain, and leucine zipper containing 1; fAd, full-length
adiponectin; gAd, globular adiponectin; G6Pase, glucose 6-phosphatase; LKB1, liver kinase B1;
PEPCK, phosphoenolpyruvate carboxykinase; PPARα, peroxisome proliferator-activated receptor
α; SCREB-P1c, sterol regulatory element binding protein 1c; TNFα, tumor necrosis factor α.
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1.3. Reactive Oxygen Species (ROS) in Adiponectin Signaling in Healthy Liver
Adiponectin signaling leads to the formation of ROS, which act as second messengers both in the
liver and in skeletal muscle [41]. Particularly in hepatocytes, the binding of gAd to receptors leads to a
transient generation of ROS involving the activation of the small GTPase Rac1 and 5-lipoxygenase
(5-LOX). This intracellular burst of ROS induces a ligand-independent transactivation of Insulin
Receptor (IR) through the oxidation and inactivation of PTP1B, a phosphotyrosine phosphatase
controlling IR phosphorylation. Downstream effects of adiponectin in hepatocytes, such as increased
glycogen synthesis, aerobic consumption of glucose, and the activation of the Mitogen Activated
Protein Kinase (MAPK) cascade, are ROS-dependent. Adiponectin signaling involving ROS formation
could partly explain the mechanism through which adiponectin exerts in vivo insulin-mimetic
effects [42].
If, on one hand, adiponectin promotes ROS production to be used as second messengers, on the
other adiponectin counteracts the excessive accumulation of oxygen products, thus impeding the
generation of intracellular oxidative stress. It has been reported that oxidative stress is harmful for
adiponectin action, i.e., in adipose tissue, adiponectin secretion is inhibited by oxidative stress [43,44].
In hepatocytes, the binding of adiponectin to its cognate receptors leads to the activation of aldehyde
oxidase-1 (AOX-1), which reduces intracellular levels of ROS through the increased activation of
PPARα [45].
2. Adiponectin in Liver Diseases
A protective action of adiponectin in liver injury is now emerging from several clinical and animal
studies. Recent studies have evaluated the relationship between adiponectin levels and some liver
diseases, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH),
hepatic fibrosis, and hepatocellular carcinoma (HCC). The findings suggest that hypoadiponectinemia
in obese people may be an important risk factor for the clinical progression of these chronic liver
diseases. NAFLD, which is the most common liver disease affecting about 20–30% of the general
population in Western countries, encompasses a wide range of liver injuries ranging from simple
steatosis, NASH, to progressive fibrosis. Furthermore, NASH may lead to liver cirrhosis and/or
HCC [46]. The onset of liver disease is caused by the deregulated production of many cytokines by
adipocyte tissue. In particular, visceral fat accumulation and an inflamed condition enhances the
serum levels of such cytokines, predisposing tissue to the onset of hepatic diseases (as TNF-α, resistin,
and leptin) and the concomitant downregulation of protective cytokines (such as adiponectin) [47].
The key molecules in adiponectin signaling that are altered in these hepatic diseases are described
below and summarized in Table 1.
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Table 1. The main effects of adiponectin in cells or signalling molecules in different liver
diseases are shown. The arrows indicate adiponectin-induced increase (up arrow) or decrease
(down arrow). Abbreviations: ACC, Acetyl-CoA carboxylase; AMPK, AMPK-activated protein kinase;
AOX-1, aldehyde oxidase-1; CPT I, Carnitine palmitoyl-transferase I; HCC, hepatocarcinoma cells;
HSC, hepatic stellate cells; IL-1β, interleukin 1-beta; IL-6, interleukin-6; IL-1RA, anti-inflammation
cytokine interleukin-1-receptor antagonist; JNK, c-Jun N-terminal kinase; PGC-1α, peroxisome
proliferator-activated receptor gamma coactivator alpha; PPARα, peroxisome proliferator-activated
receptor alpha; ROS, Reactive Oxygen Species; SIRT1, sirtuin1; SREBP-1, sterol regulatory
element-binding protein; STAT3, Signal Transducer and Activator of Transcription 3; TIMP-1, Tissue
Inhibitor of Matrix metalloproteinases-1; TGFβ, Tumour Necrosis Factor β; TNFα, Tumour Necrosis
Factor α.
ALD NASH Hepatic Fibrosis HepatocellularCarcinoma NAFLD
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2.1. Alcoholic Liver Disease (ALD)
ALD is a consequence of excessive alcohol consumption and could be considered as the
first step in the progression toward more severe for s of liver injury, including steatohepatitis,
fibrosis, and cirrh sis [48]. The dis a is characterized by the increase accumulation of fat in the liver
and several studies hav abundantly suggested a main role of adiponec n in the onset of alcoholic fatty
liver. Firstly, thanol inhibits adiponectin exp essi n nd secretion both in cultured adipocytes and
in chronically etha ol-fed n mals, hus generati g a low level of circulating adiponectin. Moreover,
chronic ethanol co sumptio in mice leads to the selective downregulation of AdipoR2 in he live [49].
Alt ough the precise mechanism leading to AdipoR2 downregulation is unknown, the involvement of
the axis sirtuin1 (Sirt1)-forkhead box O1 (F xO1) is postulat d. Indeed, FoxO1 positively regulates
AdipoR1/R2 expression [50] while Sirt1 could promote FoxO1 nuclear localization, ncreasin the
transcriptional activity [51]. Chronic ethanol exposure impairs lipid met bolism pathways triggered
by key transcriptional regulators, su h as AMPK, pe oxisome proliferator-activated receptor gamma
coactivator al ha (PGC-1α), PPARα, nd SREBP-1, leading to the excessive ccumulati n of fat
in the liver. Forcing the increase of diponectin leads to a gr at amelior tion of he pathology.
For xample, the administration of fAd to ethanol-fed mice corrected alterations in AMPK sign ling
and prevented hepatic steatosis [52]. Moreover, increased circulating adiponectin levels induced by
resveratrol were associated with enhanced hepatic expression levels of Sirt1 and reduced hepatic lipid
accumulation in chronically ethanol-fed mice [49]. The dysregulation of TNFα is greatly involved in
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the pathogenesis of alcoholic liver injury [53] and adiponectin directly opposes the damaging effects of
TNFα [33]. TNFα alters lipid metabolism by interfering with several crucial transcriptional regulators
such as AMPK and SREBP-1 [34,54]. It has been demonstrated that TNFα leads to the induction of
lipogenic enzymes in an SREBP-1-dependent manner in ethanol-exposed hepatoma cell lines [35].
Furthermore, gAd attenuates the production of TNFα and ROS in Kupffer cells exposed to ethanol [55].
Thus, adiponectin protects the liver against alcoholic injury through its anti-inflammatory activity
and counteracts hepatic liver accumulation through the antagonism of TNFα. It has been recently
reported that adiponectin levels are increased in patients with cirrhosis. In this case, increased levels
of adiponectin are associated with hepatic injury and worse prognosis in patients with alcoholic liver
disease [56].
2.2. Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD is characterized by insulin resistance (IR) and is commonly associated with obesity and
type II diabetes (T2DM). Although the pathogenesis of NAFLD is not fully elucidated, oxidative
stress, along with inflammation, plays important roles in the development and progression of the
disease. However, the main risk factor for NAFLD is considered visceral adiposity, which is associated
with an elevated circulating level of free fatty acids (FFA) and adipocyte hypertrophy. In addition,
macrophage infiltration of adipose tissue activates pro-inflammatory cytokines (such as TNFα, IL-6,
IL-1β) and nitric oxide [57]. These alterations can lead to the reduced transcription of adiponectin
mRNA and adiponectin secretion by adipocytes. Adiponectin and TNFα are mutually inhibited
when IL-6 suppresses the expression of adiponectin [58]. Several clinical studies have upheld a
role for a low circulating adiponectin level in the pathogenesis of NAFLD and confirmed the strong
association among reduced adiponectin production by adipose tissue, NAFLD, and IR, together with
the hypothesis that an imbalance between pro-inflammatory and anti-inflammatory cytokines may
have a pathogenic role in the development of liver damage in NAFLD [58].
2.3. Non-Alcoholic Steatohepatitis (NASH)
Even though obesity and/or insulin resistance are hallmarks of NASH, the specific basis of
the pathology remains to be clarified. It is certain that the progression of fatty liver (steatosis) into
NASH is associated to a chronic inflammatory state, triggered by oxidative stress along with lipid
peroxidation [36]. Indeed, steatosis is considered the first step in the onset of liver fibrosis, while the
second step is represented by mitochondrial damage that leads to ROS production followed by
peroxidation, the release of inflammatory cytokines, the death of hepatocytes, and the activation of
HSC [23].
Studies using animal models straightened the correlation among hypoadiponectinemia, steatosis,
and NASH. Feeding mice with the choline-deficient L-amino acid-defined diet, Kamada et al.
demonstrated that hepatic steatosis was more severe in adiponectin knockout (KO) mice than in
wild-type mice, while the overexpression of adiponectin resulted in the attenuation of hepatic steatosis.
Adiponectin KO mice showed enhanced expression of two rate-limiting enzymes in fatty acid synthesis,
namely ACC and fatty acid synthase, thus lacking the protective effect of adiponectin against fat
accumulation in the liver [47]. Considering adiponectin receptors, Matsunami et al. examined
the roles of hepatic AdipoR1/R2 and Insulin Receptor Substrate-1/-2 (IRS-1/-2) in the onset of
NASH [59]. Rats fed a high-fat and high-cholesterol diet for eight weeks showed the hallmarks of
NASH, namely fatty liver with inflammation and fibrosis. In this condition, the expression levels of
AdipoR1/R2 significantly decreased, whereas IRS-1 was significantly increased. Results demonstrated
that AdipoR1/R2 and IRS might be crucially important regulators for the synthesis and oxidation
of fatty acids in the liver with NASH. However, the correlation between adiponectin receptors
and NASH remains unclear, as contradictory results have been published. In fact, AdipoR1/R2
expressions has been reported to be both significantly decreased [60] and increased [61] in the onset of
NASH. The beneficial effects of adiponectin leading to the amelioration of NASH and liver fibrosis
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occurs by inhibition of Kupffer cells and HSC activation that are responsible for the secretion of
anti-inflammatory cytokines [62]. The attenuation of pro-inflammatory cytokine production due
to adiponectin in these cells is partially mediated by attenuating the translocation of NFκB to the
nucleus [63], also occurring through the adiponectin-dependent expression of the anti-inflammation
cytokine interleukin-1-receptor antagonist (IL-1RA) [64]. Wang and colleagues found that adiponectin
KO mice showed an increased lipid accumulation even under normal feeding, suggesting a possible
correlation between this pre-existing hepatic steatotic condition and dysregulated mitochondria
functions. In particular, the beneficial effects of adiponectin on mitochondria respiratory chain activities
involved uncoupling protein 2 (UCP2), a mitochondria inner membrane transporter. The level of
UCP2 is decreased in the liver of adiponectin KO mice and is significantly upregulated by adiponectin
treatment [65]. The effects of adiponectin on mitochondria respiratory chain activities are dramatically
attenuated in UCP2-deficient mice, thus suggesting that the increased UCP2 expression is mandatory
for eliciting beneficial adiponectin effects. A growing body of evidence suggests that UCP2 may
play a beneficial role in various stages of fatty liver diseases. UCP2 possesses anti-oxidant activities
through the inhibition of ROS production from mitochondria and can inhibit the production of
pro-inflammatory cytokines in both macrophage and Kupffer cells [66–68]. Although these results
suggest the existence of a reciprocal relationship between uncoupling proteins and adiponectin,
the detailed signaling mechanisms underlying adiponectin-induced UCP2 expression are not yet clear
and warrant further investigation [46].
As far as clinical studies are concerned, serum adiponectin levels have been found to be inversely
related to the presence of NASH [58]. In fact, plasma adiponectin level is decreased in patients
with steatosis and NASH, correlating with the severity of liver histology. Hypoadiponectinemia is
a characteristic feature of patients with NASH, but the cause for the further decrease of systemic
adiponectin levels during transition from fatty liver to NASH is still unclear. Patients with NASH
display damaged mitochondria and impaired oxidative phosphorylation (OxPhos) complexes [44–46].
The resulting dysfunctional mitochondrial respiratory chain triggers increased ROS level followed by
lipid peroxidation, which in turn causes steatohepatitis, necrosis, inflammation, and fibrosis. Moreover,
ROS production in steatohepatitis could directly injure mitochondrial DNA (mtDNA) and OxPhos
complexes, as well as induce NFκB activation and the hepatic synthesis of TNFα [44].
2.4. Hepatic Fibrosis
The transformation of HSC into myofibroblasts is the key step initiating the fibrotic process during
liver injury [69]. Activated HSCs, which constitutively express both AdipoR1 and AdipoR2 [70],
induce the amount of the extracellular matrix. Experimental evidences have demonstrated that
adiponectin inhibits hepatic fibrosis through the AMPK pathway, acting on multiple molecular
mechanisms responsible for the onset of pathology. Indeed, this adipokine can maintain HSC
quiescence as well as avoid their migration properties by means of the inhibition of the platelet-derived
growth factor (PDGF) stimulation [53,54]. In addition, adiponectin can also inhibit HSC activation
through the downregulation of the transforming growth factor beta 1 (TGF-β1) expression [55]. In this
context, Tomita K et al. reported a relationship between TGF-β1 and AdipoR2 expression levels,
demonstrating that the AdipoR2 silencing leads to increased TGF-β1 mRNA levels. Conversely,
AdipoR2 overexpression reduces TGF-β1 levels [71]. In agreement, AdipoR2 KO mice fed with a
methionine-choline deficient diet, which causes progressive fibrosis steatohepatitis, exhibited higher
levels of steatosis, inflammation, and fibrosis [47]. Leptin is a well described pro-fibrotic adipokine
and several studies have shown that adiponectin antagonizes leptin activity [47]. Adiponectin blocks
leptin-induced STAT3 phosphorylation in activated HSC and leptin-mediated upregulation of tissue
inhibitor of matrix metalloproteinases-1 (TIMP-1) release both in vitro and in vivo [57,72].
Fatty liver represents an important step towards the onset of liver fibrosis [73], the development
of which is greatly affected by oxidative stress. Aldehyde oxidase 1 (AOX1) activity, which has been
identified as an important source of ROS, is reduced in hepatocytes by adiponectin via the activation
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of PPARα signaling [45]. Adiponectin also increases ROS detoxifying enzymes and is involved in the
induction of superoxide dismutase 1 and catalase through AdipoR2 [74].
2.5. Hepatocellular Carcinoma (HCC)
Abusive alcohol consumption and NAFLD are important risk factors for the development of
cirrhosis and hepatocellular carcinoma (HCC) [58,75]. Recent studies showed that plasma adiponectin
levels are inversely correlated with the risk of cancers [47,76]. In clinical studies, hypoadiponectinemia
is correlated with colorectal cancer [77], gastric cancer [78], prostate cancer [79], endometrial cancer [80],
and breast cancer [81]. In addition, in vitro studies have revealed that adiponectin regulates cell
proliferation in cell lines originating from various types of cancer, including prostate cancer [82,83],
HCC [84], breast cancer [85,86], leukemia [87], and esophageal cancer [88]. Several preclinical studies
have also confirmed the involvement of adiponectin in liver tumor formation. Experiments performed
in choline-deficient mice showed that adiponectin depletion induces liver cirrhosis, thus promoting
the onset of hepatic tumor.
Saxena et al. demonstrated that adiponectin inhibits HCC cell proliferation and displays
a pro-apoptotic effect. In HCC, adiponectin stimulation activates caspase-3 and increases the
phosphorylation of c-Jun N-terminal kinase (JNK), leading to apoptosis cell death [84]. Moreover,
microarray analysis performed on human HCC pointed out an inverse correlation between adiponectin
level and tumor size [84]. Overall, the experimental evidences might suggest anti-tumor properties
of adiponectin. For example, Al-Gayyar et al. highlighted the chemoprotective and hepatoprotective
functions of adiponectin by means of the inhibition of sulfatase-2 activities [89]. Nevertheless,
the precise role of adiponectin in the onset of HCC remains to be clarified.
3. Adiponectin in Liver Regeneration and Autophagy
3.1. Adiponectin and Liver Regeneration
Beside the anti-fibrotic and anti-inflammatory effects described in the previous section,
adiponectin also displays regenerative properties in the liver. Liver is one of a few adult organs that
can regenerate after hepatic resection or other injuries. Ezaki et al. investigated liver regeneration after
partial hepatectomy in adiponectin KO mice. In particular, they demonstrated that the regeneration
process is delayed during the first 72 h in adiponectin KO mice in comparison to wild-type mice.
In agreement, the expression of cyclins D1, A2, and B1 is lower in KO than in wild-type mice.
Furthermore, hepatic triglyceride content was increased 72 h after partial hepatectomy in KO mice in
comparison to wild-type mice. The increased triglyceride level is due to impaired fatty acid oxidation
correlated with the low expression level of CPT-I and PPARα mRNAs [90]. Shu et al. obtained similar
results using a different mouse strain [91]. In particular, they observed decreased cell proliferation and
increased hepatic level of triglycerides and cholesterol. These data suggest that the downstream events
mediated by adiponectin receptors are required for the progression of liver regeneration. Interestingly,
these events seem to not include AMPK signaling, since the phosphorylation/activation of this enzyme
remains unchanged during liver regeneration.
Partial hepatectomy is known to induce the activation of different signaling pathways.
In particular, the activation of the JAK-STAT3 pathway by IL-6 plays a key role in liver regeneration [92].
Shu et al. demonstrated that in adiponectin KO mice, STAT3 phosphorylation is reduced during the
first 24–72 h after partial hepatectomy, while the level of Socs3, a protein blocking JAK-STAT3 pathway,
is increased [91], thus highlighting a prominent role of adiponectin in liver regeneration.
3.2. Adiponectin and Autophagy in Damaged Liver
Several clinical studies have proved that a low level of circulating adiponectin is an independent
risk factor for diabetes, hypertension, atherosclerosis, and NASH [93–95]. On the other hand, elevating
plasma levels of adiponectin, induced by genetic or pharmacological approaches, alleviates these
Biomedicines 2018, 6, 52 9 of 16
disorders [52,96]. Furthermore, adiponectin ameliorates other forms of liver diseases, including
alcoholic fatty liver disease and steatohepatitis [52], carbon tetrachloride and bile duct ligation-induced
cirrhosis [97], and lipopolysaccharide/D-galactosamine-induced liver injury [98]. These protective
effects of adiponectin are mediated by the direct involvement of the hormone in several processes,
including the promotion of mitochondrial fatty acid oxidation in hepatocytes [52], the suppression of
HSC activation [99], and the inhibition of pro-inflammatory cytokine production in Kupffer cells [62].
Although the precise mechanisms whereby adiponectin exerts its hepatoprotective effects have not yet
been elucidated, adiponectin-induced autophagy could play a predominant role. Indeed, autophagy
is activated as a cellular adaptive mechanism to prevent cell damage in response to liver injury.
The activation of this process ensures the removal of damaged cell structures as mitochondria,
thus protecting against mitochondria damage-induced oxidative stress and necrotic cells [100].
An association between adiponectin and autophagy activation in several cell populations has been
reported [101–104]. Under some circumstances, autophagy constitutes a stress adaptation that avoids
cell death by suppressing apoptosis, whereas in other cellular conditions, it constitutes an alternative
cell-death pathway [105]. Concerning hepatic cells, adiponectin induces the activation of autophagy to
protect hepatocytes from apoptosis induced by ethanol [106,107]. The anti-apoptotic effect elicited by
adiponectin occurs through the suppression of the ethanol-induced activation of caspase-8 and Bax
expression. AMPK plays an important role in the induction of autophagy. Indeed, AMPK silencing
blocked the adiponectin-induced expression of autophagic genes, which in turn prevented protection
from ethanol-induced apoptosis.
In addition, Lin et al. reported that adiponectin-induced autophagy plays an essential role
in maintaining the health of hepatic cells [108]. The authors showed that acetaminophen (APAP)
treatment leads to adiponectin accumulation in damaged liver and that adiponectin deficiency renders
mice more susceptible to APAP overdose-induced hepatotoxicity and mortality. These negative effects
are reverted by exogenous adiponectin replenishment. In particular, adiponectin counteracts APAP
negative effects by the activation of autophagy, thus leading to the removal of damaged mitochondria
and the amelioration of oxidative stress and necrosis. Dissecting the molecular basis, the authors
showed that the activation of autophagy by adiponectin is mediated by AMPK in primary hepatocytes.
In particular, it has been shown that AMPK activation is associated with the increased phosphorylation
of serine 317 and the decreased phosphorylation of inhibitory serine 757 of Unk51-like kinase 1 (ULK1)
mediated by the autophagic inhibitor mTOR [109]. This finding suggests that adiponectin could
promote autophagy activation indirectly via mTOR suppression. Notably, the beneficial effects due to
adiponectin-induced autophagy, namely the amelioration of APAP-induced mitochondria dysfunction
and hepatic necrosis, are completely abrogated by the genetic or pharmacological inhibition of AMPK,
suggesting that AMPK is a mandatory upstream activator of adiponectin-induced autophagy in
primary hepatocytes [108].
It is very interesting to note that the activation of autophagy is able to ameliorate several other
liver diseases, including alcoholic and non-alcoholic fatty liver diseases, liver fibrosis, and viral
hepatitis [110,111]. Notably, these diseases can be mitigated by the therapeutic administration of
adiponectin [47,112]. Therefore, the activation of autophagic processes could represent a common
mechanism whereby adiponectin exerts a protective effect against various forms of acute and chronic
liver injury.
4. Concluding Remarks
Over the last years, adiponectin has emerged as an important regulator for the development
of several hepatic diseases. In particular, hypoadiponectinemia could be considered a key factor
promoting the development of NAFLD, NASH, and hepatic tumor formation. Indeed, several animal
models of hepatic syndromes show a slight correlation between the onset of hepatic disease and
reduced circulating adiponectin levels, decreased expression of adiponectin receptors, and impaired
adiponectin-mediated signaling. Base on this, adiponectin could be considered as a biomarker of
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those hepatic pathologies, such as NAFLD, NASH, and hepatic tumor, that have been shown to be
associated with hypoadiponectinemia. On the other hand, an increase of adiponectin levels induces a
marked improvement of many liver diseases, thus demonstrating, once again, the prominent role of
adiponectin in the protection against the onset of the hepatic syndromes. Based on the beneficial effects
induced by adiponectin, future efforts must be directed towards increasing adiponectin and its hepatic
receptor levels by pharmacological strategies, involving, for example, treatment with PPARγ agonists.
Moreover, future studies should indicate whether the positive effects induced by increased levels of
adiponectin could be achieved by supplying adiponectin exogenously. Finally, a deeper study would
be useful for understanding the role in the onset of hepatic diseases of the individual multimeric forms
of adiponectin and their possible use in the amelioration/cure of these pathologies.
Author Contributions: T.G.: wrote and revised the paper; F.M.: wrote and revised the paper; A.M.: read the
paper; T.F.: planned, wrote, and revised the paper.
Acknowledgments: This work was supported by the Italian Ministry of University and Research (MIUR).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Scherer, P.E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H.F. A novel serum protein similar to C1q,
produced exclusively in adipocytes. J. Biol. Chem. 1995, 270, 26746–26749. [CrossRef] [PubMed]
2. Berner, H.S.; Lyngstadaas, S.P.; Spahr, A.; Monjo, M.; Thommesen, L.; Drevon, C.A.; Syversen, U.;
Reseland, J.E. Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004, 35, 842–849.
[CrossRef] [PubMed]
3. Shinoda, Y.; Yamaguchi, M.; Ogata, N.; Akune, T.; Kubota, N.; Yamauchi, T.; Terauchi, Y.; Kadowaki, T.;
Takeuchi, Y.; Fukumoto, S.; et al. Regulation of bone formation by adiponectin through autocrine/paracrine
and endocrine pathways. J. Cell. Biochem. 2006, 99, 196–208. [CrossRef] [PubMed]
4. Caminos, J.E.; Nogueiras, R.; Gallego, R.; Bravo, S.; Tovar, S.; García-Caballero, T.; Casanueva, F.F.; Diéguez, C.
Expression and regulation of adiponectin and receptor in human and rat placenta. J. Clin. Endocrinol. Metab.
2005, 90, 4276–4286. [CrossRef] [PubMed]
5. Piñeiro, R.; Iglesias, M.J.; Gallego, R.; Raghay, K.; Eiras, S.; Rubio, J.; Diéguez, C.; Gualillo, O.;
González-Juanatey, J.R.; Lago, F. Adiponectin is synthesized and secreted by human and murine
cardiomyocytes. FEBS Lett. 2005, 579, 5163–5169. [CrossRef] [PubMed]
6. Rodriguez-Pacheco, F.; Martinez-Fuentes, A.J.; Tovar, S.; Pinilla, L.; Tena-Sempere, M.; Dieguez, C.;
Castaño, J.P.; Malagon, M.M. Regulation of pituitary cell function by adiponectin. Endocrinology 2007,
148, 401–410. [CrossRef] [PubMed]
7. Fiaschi, T.; Magherini, F.; Gamberi, T.; Modesti, P.A.; Modesti, A. Adiponectin as a tissue regenerating
hormone: More than a metabolic function. Cell. Mol. Life Sci. 2014, 71, 1917–1925. [CrossRef] [PubMed]
8. Waki, H.; Yamauchi, T.; Kamon, J.; Ito, Y.; Uchida, S.; Kita, S.; Hara, K.; Hada, Y.; Vasseur, F.; Froguel, P.; et al.
Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and
multimer formation of adiponectin. J. Biol. Chem. 2003, 278, 40352–40363. [CrossRef] [PubMed]
9. Waki, H.; Yamauchi, T.; Kamon, J.; Kita, S.; Ito, Y.; Hada, Y.; Uchida, S.; Tsuchida, A.; Takekawa, S.;
Kadowaki, T. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic
cell line THP-1. Endocrinology 2005, 146, 790–796. [CrossRef] [PubMed]
10. Fiaschi, T.; Giannoni, E.; Taddei, M.L.; Chiarugi, P. Globular adiponectin activates motility and regenerative
traits of muscle satellite cells. PLoS ONE 2012, 7, e34782. [CrossRef] [PubMed]
11. Pajvani, U.B.; Hawkins, M.; Combs, T.P.; Rajala, M.W.; Doebber, T.; Berger, J.P.; Wagner, J.A.; Wu, M.;
Knopps, A.; Xiang, A.H.; et al. Complex distribution, not absolute amount of adiponectin, correlates with
thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2004, 279, 12152–12162.
[CrossRef] [PubMed]
12. Wang, Y.; Lam, K.S.; Chan, L.; Chan, K.W.; Lam, J.B.; Lam, M.C.; Hoo, R.C.; Mak, W.W.; Cooper, G.J.; Xu, A.
Post-translational modifications of the four conserved lysine residues within the collagenous domain of
adiponectin are required for the formation of its high molecular weight oligomeric complex. J. Biol. Chem.
2006, 281, 16391–16400. [CrossRef] [PubMed]
Biomedicines 2018, 6, 52 11 of 16
13. Pajvani, U.B.; Du, X.; Combs, T.P.; Berg, A.H.; Rajala, M.W.; Schulthess, T.; Engel, J.; Brownlee, M.; Scherer, P.E.
Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr
metabolic regulation and bioactivity. J. Biol. Chem. 2003, 278, 9073–9085. [CrossRef] [PubMed]
14. Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.;
Tsunoda, M.; et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003,
423, 762–769. [CrossRef] [PubMed]
15. Alzahrani, B.; Iseli, T.; Ramezani-Moghadam, M.; Ho, V.; Wankell, M.; Sun, E.J.; Qiao, L.; George, J.;
Hebbard, L.W. The role of AdipoR1 and AdipoR2 in liver fibrosis. Biochim. Biophys. Acta 2018, 1864, 700–708.
[CrossRef] [PubMed]
16. Thakur, V.; Pritchard, M.T.; McMullen, M.R.; Nagy, L.E. Adiponectin normalizes LPS-stimulated TNF-alpha
production by rat Kupffer cells after chronic ethanol feeding. Am. J. Physiol. Gastrointest. Liver Physiol. 2006,
290, G998–G1007. [CrossRef] [PubMed]
17. Yamauchi, T.; Iwabu, M.; Okada-Iwabu, M.; Kadowaki, T. Adiponectin receptors: A review of their structure,
function and how they work. Best Pract. Res. Clin. Endocrinol. Metab. 2014, 28, 15–23. [CrossRef] [PubMed]
18. Hug, C.; Wang, J.; Ahmad, N.S.; Bogan, J.S.; Tsao, T.S.; Lodish, H.F. T-cadherin is a receptor for hexameric
and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. USA 2004, 101, 10308–10313.
[CrossRef] [PubMed]
19. Clark, J.L.; Taylor, C.G.; Zahradka, P. Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic
Adiponectin Receptor. Endocr. Metab. Immune Disord. Drug Targets 2017, 17, 200–206. [CrossRef] [PubMed]
20. Parker-Duffen, J.L.; Nakamura, K.; Silver, M.; Kikuchi, R.; Tigges, U.; Yoshida, S.; Denzel, M.S.; Ranscht, B.;
Walsh, K. T-cadherin is essential for adiponectin-mediated revascularization. J. Biol. Chem. 2013, 288,
24886–24897. [CrossRef] [PubMed]
21. Deepa, S.S.; Dong, L.Q. APPL1: Role in adiponectin signaling and beyond. Am. J. Physiol. Endocrinol. Metab.
2009, 296, E22–E36. [CrossRef] [PubMed]
22. Mao, X.; Kikani, C.K.; Riojas, R.A.; Langlais, P.; Wang, L.; Ramos, F.J.; Fang, Q.; Christ-Roberts, C.Y.;
Hong, J.Y.; Kim, R.Y.; et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and
function. Nat. Cell Biol. 2006, 8, 516–523. [CrossRef] [PubMed]
23. Wang, Z.V.; Scherer, P.E. Adiponectin, the past two decades. J. Mol. Cell Biol. 2016, 8, 93–100. [CrossRef]
[PubMed]
24. Misra, P. AMP activated protein kinase: A next generation target for total metabolic control. Expert Opin.
Ther. Targets 2008, 12, 91–100. [CrossRef] [PubMed]
25. Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.; et al.
AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in
diet-induced insulin-resistant mice. Cell Metab. 2011, 13, 376–388. [CrossRef] [PubMed]
26. Shklyaev, S.; Aslanidi, G.; Tennant, M.; Prima, V.; Kohlbrenner, E.; Kroutov, V.; Campbell-Thompson, M.;
Crawford, J.; Shek, E.W.; Scarpace, P.J.; et al. Sustained peripheral expression of transgene adiponectin
offsets the development of diet-induced obesity in rats. Proc. Natl. Acad. Sci. USA 2003, 100, 14217–14222.
[CrossRef] [PubMed]
27. Vasiliauskaité-Brooks, I.; Sounier, R.; Rochaix, P.; Bellot, G.; Fortier, M.; Hoh, F.; De Colibus, L.; Bechara, C.;
Saied, E.M.; Arenz, C.; et al. Structural insights into adiponectin receptors suggest ceramidase activity.
Nature 2017, 544, 120–123. [CrossRef] [PubMed]
28. Holland, W.L.; Miller, R.A.; Wang, Z.V.; Sun, K.; Barth, B.M.; Bui, H.H.; Davis, K.E.; Bikman, B.T.; Halberg, N.;
Rutkowski, J.M.; et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of
adiponectin. Nat. Med. 2011, 17, 55–63. [CrossRef] [PubMed]
29. Holland, W.L.; Xia, J.Y.; Johnson, J.A.; Sun, K.; Pearson, M.J.; Sharma, A.X.; Quittner-Strom, E.; Tippetts, T.S.;
Gordillo, R.; Scherer, P.E. Inducible overexpression of adiponectin receptors highlight the roles of
adiponectin-induced ceramidase signaling in lipid and glucose homeostasis. Mol. Metab. 2017, 6, 267–275.
[CrossRef] [PubMed]
30. Sharma, A.X.; Holland, W.L. Adiponectin and its Hydrolase-Activated Receptors. J. Nat. Sci. 2017, 3, e396.
[PubMed]
31. Turpin, S.M.; Nicholls, H.T.; Willmes, D.M.; Mourier, A.; Brodesser, S.; Wunderlich, C.M.; Mauer, J.; Xu, E.;
Hammerschmidt, P.; Brönneke, H.S.; et al. Obesity-induced CerS6-dependent C16:0 ceramide production
promotes weight gain and glucose intolerance. Cell Metab. 2014, 20, 678–686. [CrossRef] [PubMed]
Biomedicines 2018, 6, 52 12 of 16
32. Wang, J.; Brymora, J.; George, J. Roles of adipokines in liver injury and fibrosis. Expert Rev. Gastroenterol.
Hepatol. 2008, 2, 47–57. [CrossRef] [PubMed]
33. Maeda, N.; Shimomura, I.; Kishida, K.; Nishizawa, H.; Matsuda, M.; Nagaretani, H.; Furuyama, N.;
Kondo, H.; Takahashi, M.; Arita, Y.; et al. Diet-induced insulin resistance in mice lacking
adiponectin/ACRP30. Nat. Med. 2002, 8, 731–737. [CrossRef] [PubMed]
34. Endo, M.; Masaki, T.; Seike, M.; Yoshimatsu, H. TNF-alpha induces hepatic steatosis in mice by enhancing
gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp. Biol. Med. 2007, 232,
614–621.
35. Pastorino, J.G.; Shulga, N. Tumor necrosis factor-alpha can provoke cleavage and activation of sterol
regulatory element-binding protein in ethanol-exposed cells via a caspase-dependent pathway that is
cholesterol insensitive. J. Biol. Chem. 2008, 283, 25638–25649. [CrossRef] [PubMed]
36. Choi, K.M.; Ryu, O.H.; Lee, K.W.; Kim, H.Y.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Choi, D.S.; Baik, S.H. Serum
adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res. Clin.
Pract. 2007, 75, 235–240. [CrossRef] [PubMed]
37. Jarrar, M.H.; Baranova, A.; Collantes, R.; Ranard, B.; Stepanova, M.; Bennett, C.; Fang, Y.; Elariny, H.;
Goodman, Z.; Chandhoke, V.; et al. Adipokines and cytokines in non-alcoholic fatty liver disease.
Aliment. Pharmacol. Ther. 2008, 27, 412–421. [CrossRef] [PubMed]
38. Latz, E.; Xiao, T.S.; Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013, 13,
397–411. [CrossRef] [PubMed]
39. Zhang, J.; Xia, L.; Zhang, F.; Zhu, D.; Xin, C.; Wang, H.; Guo, X.; Lee, Y.; Zhang, L.; Wang, S.; et al.
A novel mechanism of diabetic vascular endothelial dysfunction: Hypoadiponectinemia-induced NLRP3
inflammasome activation. Biochim. Biophys. Acta 2017, 1863, 1556–1567. [CrossRef] [PubMed]
40. Kim, M.J.; Kim, E.H.; Pun, N.T.; Chang, J.H.; Kim, J.A.; Jeong, J.H.; Choi, D.Y.; Kim, S.H.; Park, P.H. Globular
Adiponectin Inhibits Lipopolysaccharide-Primed Inflammasomes Activation in Macrophages via Autophagy
Induction: The Critical Role of AMPK Signaling. Int. J. Mol. Sci. 2017, 18. [CrossRef] [PubMed]
41. Fiaschi, T.; Cirelli, D.; Comito, G.; Gelmini, S.; Ramponi, G.; Serio, M.; Chiarugi, P. Globular adiponectin
induces differentiation and fusion of skeletal muscle cells. Cell Res. 2009, 19, 584–597. [CrossRef] [PubMed]
42. Fiaschi, T.; Buricchi, F.; Cozzi, G.; Matthias, S.; Parri, M.; Raugei, G.; Ramponi, G.; Chiarugi, P.
Redox-dependent and ligand-independent trans-activation of insulin receptor by globular adiponectin.
Hepatology 2007, 46, 130–139. [CrossRef] [PubMed]
43. Yokoyama, H.; Saito, S.; Daitoku, K.; Fukuda, I.; Higuma, T.; Hanada, H.; Osanai, T.; Okumura, K. Effects of
pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with
coronary artery disease. Fundam. Clin. Pharmacol. 2011, 25, 378–387. [CrossRef] [PubMed]
44. Saito, S.; Fujiwara, T.; Matsunaga, T.; Minagawa, K.; Fukui, K.; Fukuda, I.; Osanai, T.; Okumura, K. Increased
adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with
pravastatin: A role of the attenuation of oxidative stress. Atherosclerosis 2008, 199, 378–383. [CrossRef]
[PubMed]
45. Neumeier, M.; Weigert, J.; Schäffler, A.; Weiss, T.S.; Schmidl, C.; Büttner, R.; Bollheimer, C.; Aslanidis, C.;
Schölmerich, J.; Buechler, C. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated
by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem. Biophys. Res. Commun. 2006, 350, 731–735.
[CrossRef] [PubMed]
46. Finelli, C.; Tarantino, G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?
World J. Gastroenterol. 2013, 19, 802–812. [CrossRef] [PubMed]
47. Kamada, Y.; Takehara, T.; Hayashi, N. Adipocytokines and liver disease. J. Gastroenterol. 2008, 43, 811–822.
[CrossRef] [PubMed]
48. Sozio, M.; Crabb, D.W. Alcohol and lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E10–E16.
[CrossRef] [PubMed]
49. Ajmo, J.M.; Liang, X.; Rogers, C.Q.; Pennock, B.; You, M. Resveratrol alleviates alcoholic fatty liver in mice.
Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G833–G842. [CrossRef] [PubMed]
50. Tsuchida, A.; Yamauchi, T.; Ito, Y.; Hada, Y.; Maki, T.; Takekawa, S.; Kamon, J.; Kobayashi, M.; Suzuki, R.;
Hara, K.; et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin
sensitivity. J. Biol. Chem. 2004, 279, 30817–30822. [CrossRef] [PubMed]
Biomedicines 2018, 6, 52 13 of 16
51. Frescas, D.; Valenti, L.; Accili, D. Nuclear trapping of the forkhead transcription factor FoxO1 via
Sirt-dependent deacetylation promotes expression of glucogenetic genes. J. Biol. Chem. 2005, 280,
20589–20595. [CrossRef] [PubMed]
52. Xu, A.; Wang, Y.; Keshaw, H.; Xu, L.Y.; Lam, K.S.; Cooper, G.J. The fat-derived hormone adiponectin
alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Investig. 2003, 112, 91–100.
[CrossRef] [PubMed]
53. Yin, M.; Wheeler, M.D.; Kono, H.; Bradford, B.U.; Gallucci, R.M.; Luster, M.I.; Thurman, R.G. Essential role
of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999, 117, 942–952.
[CrossRef]
54. Steinberg, G.R.; Michell, B.J.; van Denderen, B.J.; Watt, M.J.; Carey, A.L.; Fam, B.C.; Andrikopoulos, S.;
Proietto, J.; Görgün, C.Z.; Carling, D.; et al. Tumor necrosis factor alpha-induced skeletal muscle insulin
resistance involves suppression of AMP-kinase signaling. Cell Metab. 2006, 4, 465–474. [CrossRef] [PubMed]
55. Park, P.H.; Thakur, V.; Pritchard, M.T.; McMullen, M.R.; Nagy, L.E. Regulation of Kupffer cell activity
during chronic ethanol exposure: Role of adiponectin. J. Gastroenterol. Hepatol. 2006, 21 (Suppl. 3), S30–S33.
[CrossRef] [PubMed]
56. Da Silva, T.E.; Costa-Silva, M.; Correa, C.G.; Denardin, G.; Alencar, M.L.A.; Coelho, M.S.P.H.;
Muraro-Wildner, L.; Luiza-Bazzo, M.; González-Chica, D.A.; Dantas-Correa, E.B.; et al. Clinical Significance
of Serum Adiponectin and Resistin Levels in Liver Cirrhosis. Ann. Hepatol. 2018, 17, 286–299. [CrossRef]
[PubMed]
57. Buechler, C.; Wanninger, J.; Neumeier, M. Adiponectin, a key adipokine in obesity related liver diseases.
World J. Gastroenterol. 2011, 17, 2801–2811. [PubMed]
58. Silva, T.E.; Colombo, G.; Schiavon, L.L. Adiponectin: A multitasking player in the field of liver diseases.
Diabetes Metab. 2014, 40, 95–107. [CrossRef] [PubMed]
59. Matsunami, T.; Sato, Y.; Ariga, S.; Sato, T.; Shimomura, T.; Kashimura, H.; Hasegawa, Y.; Yukawa, M.
Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin
receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model. Metabolism
2011, 60, 805–814. [CrossRef] [PubMed]
60. Kaser, S.; Moschen, A.; Cayon, A.; Kaser, A.; Crespo, J.; Pons-Romero, F.; Ebenbichler, C.F.; Patsch, J.R.;
Tilg, H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005, 54, 117–121. [CrossRef]
[PubMed]
61. Vuppalanchi, R.; Marri, S.; Kolwankar, D.; Considine, R.V.; Chalasani, N. Is adiponectin involved in the
pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J. Clin. Gastroenterol. 2005, 39,
237–242. [CrossRef] [PubMed]
62. Mandal, P.; Park, P.H.; McMullen, M.R.; Pratt, B.T.; Nagy, L.E. The anti-inflammatory effects of adiponectin
are mediated via a heme oxygenase-1-dependent pathway in rat Kupffer cells. Hepatology 2010, 51, 1420–1429.
[CrossRef] [PubMed]
63. Wulster-Radcliffe, M.C.; Ajuwon, K.M.; Wang, J.; Christian, J.A.; Spurlock, M.E. Adiponectin differentially
regulates cytokines in porcine macrophages. Biochem. Biophys. Res. Commun. 2004, 316, 924–929. [CrossRef]
[PubMed]
64. Wolf, A.M.; Wolf, D.; Rumpold, H.; Enrich, B.; Tilg, H. Adiponectin induces the anti-inflammatory cytokines
IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 2004, 323, 630–635. [CrossRef]
[PubMed]
65. Zhou, M.; Xu, A.; Tam, P.K.; Lam, K.S.; Chan, L.; Hoo, R.L.; Liu, J.; Chow, K.H.; Wang, Y. Mitochondrial
dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury.
Hepatology 2008, 48, 1087–1096. [CrossRef] [PubMed]
66. Bai, Y.; Onuma, H.; Bai, X.; Medvedev, A.V.; Misukonis, M.; Weinberg, J.B.; Cao, W.; Robidoux, J.;
Floering, L.M.; Daniel, K.W.; et al. Persistent nuclear factor-kappa B activation in Ucp2-/- mice leads
to enhanced nitric oxide and inflammatory cytokine production. J. Biol. Chem. 2005, 280, 19062–19069.
[CrossRef] [PubMed]
67. Baffy, G. Uncoupling protein-2 and non-alcoholic fatty liver disease. Front. Biosci. 2005, 10, 2082–2096.
[CrossRef] [PubMed]
Biomedicines 2018, 6, 52 14 of 16
68. Zhou, M.; Xu, A.; Tam, P.K.; Lam, K.S.; Huang, B.; Liang, Y.; Lee, I.K.; Wu, D.; Wang, Y. Upregulation of
UCP2 by adiponectin: The involvement of mitochondrial superoxide and hnRNP K. PLoS ONE 2012, 7,
e32349. [CrossRef] [PubMed]
69. Bertolani, C.; Marra, F. Role of adipocytokines in hepatic fibrosis. Curr. Pharm. Des. 2010, 16, 1929–1940.
[CrossRef] [PubMed]
70. Dong, Z.; Su, L.; Esmaili, S.; Iseli, T.J.; Ramezani-Moghadam, M.; Hu, L.; Xu, A.; George, J.; Wang, J.
Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. J. Mol. Med.
2015, 93, 1327–1339. [CrossRef] [PubMed]
71. Tomita, K.; Oike, Y.; Teratani, T.; Taguchi, T.; Noguchi, M.; Suzuki, T.; Mizutani, A.; Yokoyama, H.; Irie, R.;
Sumimoto, H.; et al. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic
steatohepatitis in mice. Hepatology 2008, 48, 458–473. [CrossRef] [PubMed]
72. Handy, J.A.; Fu, P.P.; Kumar, P.; Mells, J.E.; Sharma, S.; Saxena, N.K.; Anania, F.A. Adiponectin inhibits leptin
signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem. J. 2011, 440,
385–395. [CrossRef] [PubMed]
73. Schäffler, A.; Schölmerich, J.; Büchler, C. Mechanisms of disease: Adipocytokines and visceral adipose
tissue—Emerging role in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005, 2,
273–280. [CrossRef] [PubMed]
74. Yamauchi, T.; Nio, Y.; Maki, T.; Kobayashi, M.; Takazawa, T.; Iwabu, M.; Okada-Iwabu, M.; Kawamoto, S.;
Kubota, N.; Kubota, T.; et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin
binding and metabolic actions. Nat. Med. 2007, 13, 332–339. [CrossRef] [PubMed]
75. Adolph, T.E.; Grander, C.; Grabherr, F.; Tilg, H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple
Interactions. Int. J. Mol. Sci. 2017, 18, 1649. [CrossRef] [PubMed]
76. Dalamaga, M.; Diakopoulos, K.N.; Mantzoros, C.S. The role of adiponectin in cancer: A review of current
evidence. Endocr. Rev. 2012, 33, 547–594. [CrossRef] [PubMed]
77. Wei, E.K.; Giovannucci, E.; Fuchs, C.S.; Willett, W.C.; Mantzoros, C.S. Low plasma adiponectin levels and
risk of colorectal cancer in men: A prospective study. J. Natl. Cancer Inst. 2005, 97, 1688–1694. [CrossRef]
[PubMed]
78. Ishikawa, M.; Kitayama, J.; Kazama, S.; Hiramatsu, T.; Hatano, K.; Nagawa, H. Plasma adiponectin and
gastric cancer. Clin. Cancer Res. 2005, 11, 466–472. [PubMed]
79. Goktas, S.; Yilmaz, M.I.; Caglar, K.; Sonmez, A.; Kilic, S.; Bedir, S. Prostate cancer and adiponectin. Urology
2005, 65, 1168–1172. [CrossRef] [PubMed]
80. Petridou, E.; Mantzoros, C.; Dessypris, N.; Koukoulomatis, P.; Addy, C.; Voulgaris, Z.; Chrousos, G.;
Trichopoulos, D. Plasma adiponectin concentrations in relation to endometrial cancer: A case-control study
in Greece. J. Clin. Endocrinol. Metab. 2003, 88, 993–997. [CrossRef] [PubMed]
81. Dubois, V.; Delort, L.; Billard, H.; Vasson, M.P.; Caldefie-Chezet, F. Breast cancer and obesity: In vitro
interferences between adipokines and proangiogenic features and/or antitumor therapies? PLoS ONE 2013,
8, e58541. [CrossRef] [PubMed]
82. Fu, S.; Xu, H.; Gu, M.; Liu, C.; Wan, X.; Chen, Y.; Chen, Q.; Zhou, J.; Wang, Z. Lack of adiponectin
and adiponectin receptor 1 contributes to benign prostatic hyperplasia. Oncotarget 2017, 8, 88537–88551.
[CrossRef] [PubMed]
83. Gao, Q.; Zheng, J. Adiponectin-induced antitumor activity on prostatic cancers through inhibiting
proliferation. Cell Biochem. Biophys. 2014, 70, 461–465. [CrossRef] [PubMed]
84. Saxena, N.K.; Fu, P.P.; Nagalingam, A.; Wang, J.; Handy, J.; Cohen, C.; Tighiouart, M.; Sharma, D.;
Anania, F.A. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and
inhibits hepatocellular carcinoma. Gastroenterology 2010, 139, 1762–1773.e5. [CrossRef] [PubMed]
85. Fletcher, S.J.; Sacca, P.A.; Pistone-Creydt, M.; Coló, F.A.; Serra, M.F.; Santino, F.E.; Sasso, C.V.;
Lopez-Fontana, C.M.; Carón, R.W.; Calvo, J.C.; et al. Human breast adipose tissue: Characterization
of factors that change during tumor progression in human breast cancer. J. Exp. Clin. Cancer Res. 2017, 36, 26.
[CrossRef] [PubMed]
86. Ding, Y.; Cao, Y.; Wang, B.; Wang, L.; Zhang, Y.; Zhang, D.; Chen, X.; Li, M.; Wang, C. APPL1-Mediating
Leptin Signaling Contributes to Proliferation and Migration of Cancer Cells. PLoS ONE 2016, 11, e0166172.
[CrossRef] [PubMed]
Biomedicines 2018, 6, 52 15 of 16
87. Wu, S.; Zheng, C.; Chen, S.; Lin, B.; Chen, Y.; Zhou, W.; Li, Z. Adiponectin signals through Adiponectin
Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells. Biochem. Biophys.
Res. Commun. 2015, 456, 367–372. [CrossRef] [PubMed]
88. Konturek, P.C.; Burnat, G.; Rau, T.; Hahn, E.G.; Konturek, S. Effect of adiponectin and ghrelin on apoptosis
of Barrett adenocarcinoma cell line. Dig. Dis. Sci. 2008, 53, 597–605. [CrossRef] [PubMed]
89. Al-Gayyar, M.M.; Abbas, A.; Hamdan, A.M. Chemopreventive and hepatoprotective roles of adiponectin
(SULF2 inhibitor) in hepatocelluar carcinoma. Biol. Chem. 2016, 397, 257–267. [CrossRef] [PubMed]
90. Ezaki, H.; Yoshida, Y.; Saji, Y.; Takemura, T.; Fukushima, J.; Matsumoto, H.; Kamada, Y.; Wada, A.; Igura, T.;
Kihara, S.; et al. Delayed liver regeneration after partial hepatectomy in adiponectin knockout mice.
Biochem. Biophys. Res. Commun. 2009, 378, 68–72. [CrossRef] [PubMed]
91. Shu, R.Z.; Zhang, F.; Wang, F.; Feng, D.C.; Li, X.H.; Ren, W.H.; Wu, X.L.; Yang, X.; Liao, X.D.; Huang, L.; et al.
Adiponectin deficiency impairs liver regeneration through attenuating STAT3 phosphorylation in mice.
Lab. Investig. 2009, 89, 1043–1052. [CrossRef] [PubMed]
92. Li, W.; Liang, X.; Kellendonk, C.; Poli, V.; Taub, R. STAT3 contributes to the mitogenic response of hepatocytes
during liver regeneration. J. Biol. Chem. 2002, 277, 28411–28417. [CrossRef] [PubMed]
93. Hui, X.; Lam, K.S.; Vanhoutte, P.M.; Xu, A. Adiponectin and cardiovascular health: An update. Br. J.
Pharmacol. 2012, 165, 574–590. [CrossRef] [PubMed]
94. Musso, G.; Gambino, R.; Biroli, G.; Carello, M.; Fagà, E.; Pacini, G.; De Michieli, F.; Cassader, M.; Durazzo, M.;
Rizzetto, M.; et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell
dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2005,
100, 2438–2446. [CrossRef] [PubMed]
95. Weyer, C.; Funahashi, T.; Tanaka, S.; Hotta, K.; Matsuzawa, Y.; Pratley, R.E.; Tataranni, P.A.
Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and
hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001, 86, 1930–1935. [CrossRef] [PubMed]
96. Satoh, H.; Nguyen, M.T.; Trujillo, M.; Imamura, T.; Usui, I.; Scherer, P.E.; Olefsky, J.M. Adenovirus-mediated
adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes 2005, 54,
1304–1313. [CrossRef] [PubMed]
97. Kamada, Y.; Tamura, S.; Kiso, S.; Matsumoto, H.; Saji, Y.; Yoshida, Y.; Fukui, K.; Maeda, N.; Nishizawa, H.;
Nagaretani, H.; et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin.
Gastroenterology 2003, 125, 1796–1807. [CrossRef] [PubMed]
98. Masaki, T.; Chiba, S.; Tatsukawa, H.; Yasuda, T.; Noguchi, H.; Seike, M.; Yoshimatsu, H. Adiponectin protects
LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004, 40,
177–184. [CrossRef] [PubMed]
99. Shafiei, M.S.; Shetty, S.; Scherer, P.E.; Rockey, D.C. Adiponectin regulation of stellate cell activation via
PPARγ-dependent and -independent mechanisms. Am. J. Pathol. 2011, 178, 2690–2699. [CrossRef] [PubMed]
100. Yan, S.; Huda, N.; Khambu, B.; Yin, X.M. Relevance of autophagy to fatty liver diseases and potential
therapeutic applications. Amino Acids 2017, 49, 1965–1979. [CrossRef] [PubMed]
101. Essick, E.E.; Wilson, R.M.; Pimentel, D.R.; Shimano, M.; Baid, S.; Ouchi, N.; Sam, F. Adiponectin modulates
oxidative stress-induced autophagy in cardiomyocytes. PLoS ONE 2013, 8, e68697. [CrossRef] [PubMed]
102. Habeeb, B.S.; Kitayama, J.; Nagawa, H. Adiponectin supports cell survival in glucose deprivation through
enhancement of autophagic response in colorectal cancer cells. Cancer Sci. 2011, 102, 999–1006. [CrossRef]
[PubMed]
103. Qi, G.M.; Jia, L.X.; Li, Y.L.; Li, H.H.; Du, J. Adiponectin suppresses angiotensin II-induced inflammation and
cardiac fibrosis through activation of macrophage autophagy. Endocrinology 2014, 155, 2254–2265. [CrossRef]
[PubMed]
104. Gamberi, T.; Modesti, A.; Magherini, F.; D’Souza, D.M.; Hawke, T.; Fiaschi, T. Activation of autophagy
by globular adiponectin is required for muscle differentiation. Biochim. Biophys. Acta 2016, 1863, 694–702.
[CrossRef] [PubMed]
105. Maiuri, M.C.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: Crosstalk between autophagy
and apoptosis. Nat. Rev. Mol. Cell Biol. 2007, 8, 741–752. [CrossRef] [PubMed]
106. Nepal, S.; Kim, M.J.; Lee, E.S.; Kim, J.A.; Choi, D.Y.; Sohn, D.H.; Lee, S.H.; Song, K.; Kim, S.H.; Jeong, G.S.; et al.
Modulation of Atg5 expression by globular adiponectin contributes to autophagy flux and suppression of
ethanol-induced cell death in liver cells. Food Chem. Toxicol. 2014, 68, 11–22. [CrossRef] [PubMed]
Biomedicines 2018, 6, 52 16 of 16
107. Nepal, S.; Park, P.H. Activation of autophagy by globular adiponectin attenuates ethanol-induced apoptosis
in HepG2 cells: Involvement of AMPK/FoxO3A axis. Biochim. Biophys. Acta 2013, 1833, 2111–2125.
[CrossRef] [PubMed]
108. Lin, Z.; Wu, F.; Lin, S.; Pan, X.; Jin, L.; Lu, T.; Shi, L.; Wang, Y.; Xu, A.; Li, X. Adiponectin protects against
acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice.
J. Hepatol. 2014, 61, 825–831. [CrossRef] [PubMed]
109. Kim, J.; Kundu, M.; Viollet, B.; Guan, K.L. AMPK and mTOR regulate autophagy through direct
phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13, 132–141. [CrossRef] [PubMed]
110. Rautou, P.E.; Mansouri, A.; Lebrec, D.; Durand, F.; Valla, D.; Moreau, R. Autophagy in liver diseases.
J. Hepatol. 2010, 53, 1123–1134. [CrossRef] [PubMed]
111. Tacke, F.; Trautwein, C. Controlling autophagy: A new concept for clearing liver disease. Hepatology 2011, 53,
356–358. [CrossRef] [PubMed]
112. Palmer, C.; Hampartzoumian, T.; Lloyd, A.; Zekry, A. A novel role for adiponectin in regulating the immune
responses in chronic hepatitis C virus infection. Hepatology 2008, 48, 374–384. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
